Stock Track | NewAmsterdam Pharma (NAMS) Soars 5% as Analysts Maintain Buy Ratings with High Price Targets

Stock Track11-10

NewAmsterdam Pharma Company NV (NAMS) shares are soaring 5.09% in pre-market trading on Monday, buoyed by positive analyst coverage. The biopharmaceutical company's stock is gaining momentum following reaffirmed Buy ratings from two prominent financial firms.

RBC Capital analyst Leonid Timashev reiterated a Buy rating on NewAmsterdam Pharma, setting a price target of $44.00. This vote of confidence was echoed by Piper Sandler analyst Yasmeen Rahimi, who also maintained a Buy rating with an even more optimistic price target of $60.00. These price targets suggest significant upside potential from the stock's current trading levels.

The sustained bullish outlook from multiple analysts underscores investor confidence in NewAmsterdam Pharma's future prospects. As a biopharmaceutical company, positive analyst sentiment often reflects optimism about the company's drug pipeline or ongoing clinical trials. Investors appear to be responding favorably to these analyst reports, driving the stock's pre-market surge.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1180787541?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 22:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180787541","market":"us","top_or_hot":-1,"title":"Stock Track | NewAmsterdam Pharma (NAMS) Soars 5% as Analysts Maintain Buy Ratings with High Price Targets","media":"Stock Track","content":"<p>NewAmsterdam Pharma Company NV (NAMS) shares are soaring 5.09% in pre-market trading on Monday, buoyed by positive analyst coverage. The biopharmaceutical company's stock is gaining momentum following reaffirmed Buy ratings from two prominent financial firms.</p>\n\n<p>RBC Capital analyst Leonid Timashev reiterated a Buy rating on NewAmsterdam Pharma, setting a price target of $44.00. This vote of confidence was echoed by Piper Sandler analyst Yasmeen Rahimi, who also maintained a Buy rating with an even more optimistic price target of $60.00. These price targets suggest significant upside potential from the stock's current trading levels.</p>\n\n<p>The sustained bullish outlook from multiple analysts underscores investor confidence in NewAmsterdam Pharma's future prospects. As a biopharmaceutical company, positive analyst sentiment often reflects optimism about the company's drug pipeline or ongoing clinical trials. Investors appear to be responding favorably to these analyst reports, driving the stock's pre-market surge.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | NewAmsterdam Pharma (NAMS) Soars 5% as Analysts Maintain Buy Ratings with High Price Targets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | NewAmsterdam Pharma (NAMS) Soars 5% as Analysts Maintain Buy Ratings with High Price Targets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-10 22:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NewAmsterdam Pharma Company NV (NAMS) shares are soaring 5.09% in pre-market trading on Monday, buoyed by positive analyst coverage. The biopharmaceutical company's stock is gaining momentum following reaffirmed Buy ratings from two prominent financial firms.</p>\n\n<p>RBC Capital analyst Leonid Timashev reiterated a Buy rating on NewAmsterdam Pharma, setting a price target of $44.00. This vote of confidence was echoed by Piper Sandler analyst Yasmeen Rahimi, who also maintained a Buy rating with an even more optimistic price target of $60.00. These price targets suggest significant upside potential from the stock's current trading levels.</p>\n\n<p>The sustained bullish outlook from multiple analysts underscores investor confidence in NewAmsterdam Pharma's future prospects. As a biopharmaceutical company, positive analyst sentiment often reflects optimism about the company's drug pipeline or ongoing clinical trials. Investors appear to be responding favorably to these analyst reports, driving the stock's pre-market surge.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NAMS","symbol_name":"NEWAMSTERDAM PHARMA CO NV","start_time":0,"source_url":"","article_id":"1180787541","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180787541","pubTimestamp":1762785382,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"NewAmsterdam Pharma Company NV (NAMS) shares are soaring 5.09% in pre-market trading on Monday, buoyed by positive analyst coverage. The biopharmaceutical company's stock is gaining momentum...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NAMS":"NEWAMSTERDAM PHARMA CO NV"},"translate_title":"股票追踪|NewAmsterdam Pharma(NAMS)飙升5%，分析师维持买入评级和高目标价","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NAMS":1},"content_text":"NewAmsterdam Pharma Company NV (NAMS) shares are soaring 5.09% in pre-market trading on Monday, buoyed by positive analyst coverage. The biopharmaceutical company's stock is gaining momentum following reaffirmed Buy ratings from two prominent financial firms.\nRBC Capital analyst Leonid Timashev reiterated a Buy rating on NewAmsterdam Pharma, setting a price target of $44.00. This vote of confidence was echoed by Piper Sandler analyst Yasmeen Rahimi, who also maintained a Buy rating with an even more optimistic price target of $60.00. These price targets suggest significant upside potential from the stock's current trading levels.\nThe sustained bullish outlook from multiple analysts underscores investor confidence in NewAmsterdam Pharma's future prospects. As a biopharmaceutical company, positive analyst sentiment often reflects optimism about the company's drug pipeline or ongoing clinical trials. Investors appear to be responding favorably to these analyst reports, driving the stock's pre-market surge.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1180787541","isCrawlerRequest":true}